Dr. Adi Barzel

T cell engineering for Cancer immunotherapy has shown clinical success, but it is not applied to most patients in need, because the process can only be performed in specialized centers. In addition, B cell engineering has not shown therapeutic efficacy to date. The Adi Barzel lab at TAU developed a novel immunotherapy approach, targeting immune genes into the genome of white blood cells. In particular, the team targets chimeric antigen receptor or T cell receptor genes into the genome of T cells, and targets antibody genes into the genome of B cells. This novel targeting method promises to revolutionize cancer immunotherapy as it allows safe, efficient and scalable engineering of B cells and T cells


Contact info:
Adi Barzel, PhD
George S. Wise Faculty of Life Sciences



Tel Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel
UI/UX Basch_Interactive